Business opportunity
Immune Targeting Systems is open to discussions in the following areas for potential commercial development;
1. Existing pipeline vaccine candidates
2. Licensing of the fluoropeptide delivery system for non-core vaccine candidates
3. Vaccine antigen-epitope identification for non-core diseases.
Investors & Stakeholders
ITS raised a £4.0m Series-A private equity funding round in June 2007 and an Exceptional Development Grant of £500,000 from the London Development Agency.
Key investors include:Key Stakeholders
